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ttp://dx.doi.org/10.1016/j.jmoldx.2013.04.007The pathognomonic genetic alteration in chronic myeloid leukemia is the formation of the BCR-
ABL1 fusion gene, which produces a constitutively active tyrosine kinase that drives leukemic
transformation. Targeted tyrosine kinase inhibitor treatment with imatinib, nilotinib, dasatinib,
bosutinib, and ponatinib is the cornerstone of modern therapy for this hematologic malignancy.
Real-time quantitative RT-PCR (RT-qPCR, also RQ-PCR) of BCR-ABL1 RNA is a necessary laboratory
technique for monitoring the efﬁcacy of tyrosine kinase inhibitor therapy and quantitatively
assessing minimal residual disease. The molecular response measured by BCR-ABL1 RT-qPCR assists
in identifying suboptimal responses and can help inform the decision to switch to alternative
therapies that may be more efﬁcacious (or to pursue more stringent monitoring). Furthermore, the
tyrosine kinase inhibitoremediated molecular response provides valuable risk stratiﬁcation and
prognostic information on long-term outcomes. Despite these attributes, informed, universal,
practical utilization of this well-established monitoring test will require heightened efforts by the
molecular diagnostics laboratory community to adopt the standardized reporting units of the
International Scale. Without widespread adoption of the International Scale, the consensus major
molecular response and early molecular response treatment thresholds will not be deﬁnable, and
optimal clinical outcomes for patients with chronic myeloid leukemia may not be achieved.
(J Mol Diagn 2013, 15: 565e576; http://dx.doi.org/10.1016/j.jmoldx.2013.04.007)Supported by Novartis Pharmaceuticals Corporation for medical editorial
assistance.
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support from Novartis and Bristol-Myers Squibb.Virtually all patients with chronic myeloid leukemia (CML),
a hematologic cancer characterized by the overproduction
of immature and mature myeloid cells in the peripheral
blood, spleen, and bone marrow, carry the Philadelphia
chromosome (Ph), a reciprocal translocation between the
Abelson gene (ABL1) on chromosome 9 and the breakpoint
cluster region gene (BCR) on chromosome 22.1,2 The
resulting fusion gene, BCR-ABL1, produces a constitutively
active chimeric tyrosine kinase that is required to initiate,
propagate, and maintain the leukemic phenotype in patients
with CML. Tyrosine kinase inhibitor (TKI) therapy targets
the BCR-ABL1 kinase and over the past decade has become
the recommended ﬁrst-line treatment approach for patients
newly diagnosed in the initial chronic phase (CP) of CML.
The success of TKI therapy in CML has furthermore
become the scientiﬁc paradigm for molecularly targeted
therapy of other cancers in the 21st century.3stigative Pathology
.Since the advent of BCR-ABL1 TKIs, patients with CML
have had signiﬁcantly improved prognosis, as reﬂected by
longer median overall survival (OS) and lower rates of
disease progression, compared with previous therapeutic
regimens.4e6 Imatinib was the ﬁrst TKI approved by the US
Food and Drug Administration for CML, based on the phase
3 International Randomized Study of Interferon and STI571
(IRIS) clinical trial. Long-term follow-up of CML-CP
patients treated with ﬁrst-line imatinib showed a progres-
sion-free survival (PFS) rate of 93% at 5 years7 and an
Press et alestimated OS rate of 85% at 8 years (93% when only CML-
related deaths were considered).8
Although most patients treated with imatinib have
durable responses, resistance to imatinib does occur in some
patients, most commonly through development of mutations
in the BCR-ABL1 kinase domain that abrogate imatinib-
induced inhibition.9e12 Dasatinib and nilotinib, more
potent TKIs than imatinib, were initially approved by the
Food and Drug Administration for the treatment of CML
after imatinib failure or intolerance. More recently, both
dasatinib and nilotinib have demonstrated, in separate phase
3 trials, superior response rates and higher rates of PFS as
ﬁrst-line therapy, compared with imatinib.13e17 In addition,
rates of major molecular response (MMR) were signiﬁcantly
higher with dasatinib or nilotinib versus imatinib over each
of 3 years of follow-up.13,14,16,17 Two other TKIs, bosutinib
and ponatinib, were recently approved for second- and third-
line treatment of CML.18,19
Targeted therapy with TKIs dramatically reduces the
leukemic cell burden in CML.20e25 The low levels of
minimal residual disease (MRD) typically achieved during
TKI therapy demand a sensitive monitoring assay for reliable
detection and quantitation.26 Real-time quantitative RT-PCR
(RT-qPCR, also RQ-PCR) has proven to be an effective and
clinically validated laboratory method to quantify BCR-ABL1
transcript levels and assess molecular responses. Further-
more, given the predictive value of molecular response for
long-term clinical outcomes and as a direct biomarker for
drug efﬁcacy and response, RT-qPCR has become an integral
component of CML disease management.22e25
As BCR-ABL1 RT-qPCRebased molecular monitoring
evolves, a number of factors have been identiﬁed as
potential sources of confusion, thus limiting this assay’s
practical clinical utility. In the quest to improve the labo-
ratory utility of CML molecular monitoring, the following
questions need to be addressed:
1. What are the clinically relevant BCR-ABL1 threshold
levels for predicting TKI treatment responses and long-
term PFS?
2. What are the clinically relevant BCR-ABL1 threshold levels
for predicting suboptimal response, loss of response, and
evolving drug resistance?
3. What laboratory-speciﬁc factors limit the precision,
accuracy, and sensitivity of the BCR-ABL1 RT-qPCR
assay?
4. How can the BCR-ABL1 RT-qPCR assay be standardized
to the International Scale (IS) of measurement by which
clinically relevant threshold levels have already been
deﬁned?
This review discusses the current use of molecular
monitoring in the management of patients with CML
receiving TKIs, its practical utility for measuring treatment
response (and nonresponse), and the remaining challenges
for improving molecular monitoring. The lessons learned
from the extensive research on molecular monitoring of566BCR-ABL1 will beneﬁt, not only patients with CML, but
also patients with other cancers, for which a variety of
molecularly targeted therapies and companion diagnostics
are now becoming available.
What Are the Clinically Relevant BCR-ABL1
Threshold Levels for Predicting TKI Treatment
Responses and Long-Term PFS?
Monitoring Response to Therapy
The clinical utility of laboratory methods for monitoring TKI
therapeutic efﬁcacy, including hematologic, cytogenetic, and
PCR-based techniques, depends largely on their limits of
detection. Complete hematologic response is based on
normalization of peripheral blood counts [National
Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines in Oncology (NCCN Guidelines) Chronic
Myelogenous Leukemia Version 3.2013. http://www.nccn.
org/professionals/physician_gls/pdf/cml.pdf, last accessed
February 24, 2013; user registration required].27 Cytogenetic
response is based on the percentage of Ph-positive (Phþ)
metaphase cells observed in a bone marrow sample, typically
by Giemsa staining of metaphase chromosome spreads.
Complete cytogenetic response (CCyR), a clinically impor-
tant prognostic response threshold in patients with CML
receiving TKIs, is deﬁned as the absence of detectable Phþ
chromosomes (NCCN Guidelines).28,29 Because a minimum
of 20 metaphase cells is recommended for cytogenetic eval-
uation (NCCN Guidelines), the limit of detection of this
technique is relatively low (1:20, or 5%). Another limitation
of cytogenetic testing is the need for an invasive bone marrow
biopsy to obtain culturable metaphase cells. Cytogenetic
testing does have, however, the capability to detect other
chromosomal abnormalities besides the Ph chromosome, and
this may have prognostic relevance. Ancillary interphase cell
ﬂuorescence in situ hybridization (FISH), with DNA probes
for BCR and ABL1, is also commonly used to monitor CML
response to treatment. Because 100 to 500 interphase cells are
typically examinedwith FISH, this approach ismore sensitive
(1:500 to 1:100, or 0.2 to 1%) than metaphase cytogenetics.
Depending on the probes used, however, it can have a high
false-positive rate. FISH lacks practical utility for MRD
monitoring in the majority of TKI-treated CML patients, and
therefore is not recommended by the NCCN for routine
monitoring of TKI treatment response (NCCN Guidelines).
Instead, guidelines from the NCCN, the European Leu-
kemiaNet (ELN),27 and the National Institutes of Health21
recommend serial BCR-ABL1 RT-qPCR assays at regular
3- to 6-month intervals for routine MRD monitoring of
CML patients receiving TKI therapy. Molecular monitoring
involves extraction of RNA from a bone marrow or
peripheral blood specimen and subsequent RT-qPCR to
measure transcript levels of BCR-ABL1 relative to those of
a reference gene. Because the analyte of RT-qPCR, RNA, is
labile and degradation prone, many pre-analytical variablesjmd.amjpathol.org - The Journal of Molecular Diagnostics
Monitoring Molecular Response in CMLcan affect sample quality and quantitative results, including
sample source (peripheral blood versus bonemarrow), sample
storage (temperature, type of tube), sample transport (duration
of travel, temperature), and sample stabilization (lysis buffer,
storage buffer). The reference gene in RT-qPCR serves as
a control for overall RNA quality (with respect to degrada-
tion) and, assuming equivalent reference gene expression in
all hematopoietic cells, for the number of input cells per PCR
reaction. For example, in our laboratory, when the level of
reference gene RNA falls two SD below the mean, RT-qPCR
for the BCR-ABL1 and reference gene are repeated, and if this
repeat analysis again shows low reference gene RNA levels,
the sample is reported as inadequate (new sample requested).
Compared with cytogenetic testing, PCR-based molecular
monitoring offers exquisite analytical sensitivity, 100 to 1000
times greater than FISH or bonemarrow cytogenetic analysis.
It is applicable to bone marrow and peripheral blood samples,
andwith a short turnaround time, provides quantitative results
that are associated with validated clinical response thresh-
olds.30 Disadvantages of RT-qPCR include its lack of meth-
odological and reporting standardization, its need for
specialized laboratories and equipment, and the variability of
analytical and reporting systems.31 Table 1 summarizes
current NCCN testing recommendations for monitoring TKI
treatment response in patients with CML.
Key Levels of Molecular Response
Response to TKI therapy is assessed by the change in BCR-
ABL1 transcript levels from a standardized pretreatment
baseline level. The standardized baseline, deﬁned as 100% onTable 1 Recommended Testing Parameters for Patients on TKI Therap
Test Recommended test speciﬁcations
Bone marrow
cytogenetics
Analyze 20 metaphase cells
FISH Use peripheral blood
Use dual probes for BCR and ABL1 genes
RT-qPCR Use an RT-qPCR (IS) assay with sensitivity
of 4.5 log below the standardized baselin
Use peripheral blood or bone marrow
BCR-ABL1 KD
mutational analysis
None provided
*Level of response that warrants further patient evaluation and consideration
CCyR, complete cytogenetic response; CML, chronic myeloid leukemia; FISH, ﬂu
MMR, major molecular response.
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in which the three participating laboratories independently
determined the median BCR-ABL1 RT-qPCR value of the
same set of 30 CML-CP samples collected before imatinib
treatment initiation.32 Thus, 100% BCR-ABL1 (IS) became
the standardized baseline against which future BCR-ABL1
RNA levels were compared, and any treatment-associated
reduction in BCR-ABL1 would represent an absolute reduc-
tion that is independent of individual patient-speciﬁc
BCR-ABL1 baseline values. MMR, a 3-log reduction in
BCR-ABL1 transcript levels from this standardized baseline,
is deﬁned as 0.1% on the IS (NCCN Guidelines), and
represents a clinically relevant level of molecular response,
based on the observation that patients who achieved MMR
had a minimal risk of disease progression and improved long-
term PFS compared with patients who did not.32
Achievement of MMR has been incorporated into ELN
practice guidelines to deﬁne an optimal level of response at
12 to 18 months (Table 2),27,33 and failure to achieve this
molecular response milestone is considered a suboptimal
response that calls for careful reevaluation of the current
therapeutic regimen.27,33 Analysis of IRIS data at 7 years
demonstrated that patients who had achieved MMR by 12 or
18 months had signiﬁcantly superior event-free survival and
OS, and more durable CCyR, compared with those who had
not.24 Another study showed that patients on imatinib with
2-log reduction in BCR-ABL1 levels at the time of CCyR
had longer PFS than patients not achieving that level of
molecular response.25 In the German CML-Study IV of
patients on imatinib, MMR at 12 months predicted signiﬁ-
cantly better PFS and OS at 3 years.23 Further analysis of thisy per NCCN Guidelines
Recommended test frequency
At diagnosis
At 3 months, if RT-qPCR (IS) is not available
At 12 months, if neither CCyR nor MMR is achieved
At 18 months, if no MMR and no CCyR at 12 months
1-log increase in BCR-ABL1 level without MMR
At diagnosis, if collection of bone marrow is not feasible
Not recommended for monitoring response to treatment
e
At diagnosis
Every 3 months for responding patients
After CCyR is achieved, every 3 months for 3 years, then
every 3 to 6 months thereafter
If 1-log increase in BCR-ABL1 level with MMR, repeat in
1 to 3 months
If inadequate* response to ﬁrst-line therapy or any sign
of loss of response, deﬁned as hematologic or
cytogenetic relapse, or 1-log increase in BCR-ABL1 level
and loss of MMR
If disease progression to accelerated or blast phase CML
of a change in therapy.
orescence in situ hybridization; IS, international scale; KD, kinase domain;
567
Table 2 Expected Levels of Response to First-line TKI Therapy (per NCCN and ELN27,33 Guidelines)
Time on
therapy
NCCN Guidelines (v3.2013) ELN Guidelines (2009, updated 2013)*
Adequate response Inadequate response Optimal response
Suboptimal response
(“warning”)
Failure (therapy
change indicted)
3 Months 10% BCR-ABL1
(IS) or PCyR
>10% BCR-ABL1 (IS)
or <PCyR
CHR and PCyR; 10%
BCR-ABL1 (IS)
Ph+ 36e95%; >10%
BCR-ABL1 (IS)
<CHR; No CyR
6 Months NS NS CCyR; <1% BCR-ABL1 (IS) Phþ 1e35%; 1e10%
BCReABL1 (IS)
<PCyR; >10%
BCR-ABL1 (IS)
12 Months CCyR PCyR or cytogenetic
relapse
MMR 0.1e1% BCR-ABL1 (IS) <CCyR; >1%
BCR-ABL1 (IS)
18 Months CCyR PCyR or cytogenetic
relapse
Anytime NS NS Stable or improving MMR Loss of CHR, MMR, or
CCyR; KD mutations;
clonal progression
*After this article was accepted, an updated version of the consensus European LeukemiaNet (ELN) recommendations for management of chronic myeloid
leukemia was published.33 This table reﬂects those changes. Also see Note Added in Proof.
CCyR, complete cytogenetic response (0% Phþ); ELN, European LeukemiaNet; IS, international scale; mCyR, minor cytogenetic response; MMR, major
molecular response; No CyR, no cytogenetic response; NS, not speciﬁed; PCyR, partial cytogenetic response; Ph, Philadelphia chromosome.
Press et alstudy also showed better outcomes for patients with lower
BCR-ABL1 transcript levels at 3 months after TKI initiation;
the 5-year OS and PFS rates were signiﬁcantly longer for
patients with 10% BCR-ABL1 (IS) at 3 months than for
patients with >10% BCR-ABL1 (IS).34 Attainment of a 1-
log BCR-ABL1 transcript reduction, or 10% BCR-ABL1
(IS), at 3 months after TKI initiation is now deﬁned as an
early molecular response. The practical prognostic value of
early molecular response has been independently conﬁrmed
in a British CML cohort, where patients who failed to attain
this level of response had signiﬁcantly shorter OS and PFS at
8 years than patients who did attain this early molecular
response landmark.35 On the basis of these data, the most
recent NCCN CML guidelines speciﬁcally recommend
a change in treatment for patients who fail to reach 10% BCR-
ABL1 (IS) after 3 months of TKI therapy (Table 2).
Molecular response to nilotinib or dasatinib has also been
shown to predict long-term outcomes. For CML-CP patients
receiving ﬁrst-line dasatinib, an early molecular response was
predictive of improved long-term outcomes at 2 years.35
Similarly, CML-CP patients receiving ﬁrst-line nilotinib
who achieved early molecular response had higher rates of
molecular response and improved PFS andOS at 2 and 3 years
than patients who did not achieve early molecular response.36
In the second-line setting, patients receiving nilotinib after
imatinib failure who achieved 10% BCR-ABL1 (IS) at 3
months had higher 24-month event-free survival rates than
patients with >10% BCR-ABL1 (IS) at 3 months.37
Complete molecular response (CMR) has been deﬁned as
a level of BCR-ABL1 RNA that is undetectable by RT-qPCR.
Because the absence of detectable BCR-ABL1 may be due to
pre-analytical factors, such as sample degradation, or to tech-
nical factors, such as the variability in the limits of detection of
heterogeneous laboratory-developed assays, the deﬁnition of
CMR is very much sample- and laboratory-dependent. To568address these issues, it has been proposed that a ﬁnding of
undetectable BCR-ABL1 be qualiﬁed by the log limit of
detection of the assay as deﬁned by the transcript level of the
reference gene [eg, CMR4 Z undetectable BCR-ABL1 in
a sample in which BCR-ABL1 RNA would have been detect-
able, had it been present at a level above 0.01% IS (4 log below
baseline)].38 In the Oregon Health & Science University
(OHSU) laboratory, the cutoff sample quality threshold for
deﬁning CMR is a 4.7-log reduction from baseline [0.002%
BCR-ABL1 (IS)], as deﬁned by the reference gene level.
Approximately 10% of samples submitted to the OHSU
laboratory have reference gene transcript levels below this 4.7-
log threshold such that even though BCR-ABL1 may be
undetectable in these samples, they are not reported as having
achieved CMR. By comparison, NCCN Guidelines deﬁne
CMR as undetectable BCR-ABL1 RNA with a minimal
analytical assay sensitivity of 4.5 log below the standardized IS
baseline.
Given that the achievement of 10% BCR-ABL1 (IS) at 3
months and 0.1% BCR-ABL1 (IS) (ie, MMR) at 18
months predict good prognosis, would achieving undetect-
able BCR-ABL1 predict even better clinical outcomes? In
support of this hypothesis, achieving CMR has been shown
to be associated with more durable remissions and signiﬁ-
cantly longer relapse-free survival than achieving MMR
without CMR.39 Other studies have shown that the
frequency of CMR increases with longer treatment times,
and that the achievement of MMR at 12 months predicts
subsequent CMR.40 In the Stop Imatinib (STIM) study,
a prospective study evaluating the feasibility of stopping
imatinib treatment in patients with durable CMR, 12 months
after discontinuation of imatinib, 41% of patients with
12 months of follow-up maintained CMR.41 Thus, 59% of
patients regained PCR-detectable BCR-ABL1 RNA after ima-
tinib discontinuation. The long-term prognostic signiﬁcance ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
Monitoring Molecular Response in CMLundetectable BCR-ABL1 is actively being researched to better
understand its implications.
What Are the Clinically Relevant BCR-ABL1
Threshold Levels for Predicting Suboptimal
Response, Loss of Response, and Evolving Drug
Resistance?
If achieving MMR signals a good long-term outcome, does
loss of MMR suggest impending resistance or relapse?42,43
In general, rising BCR-ABL1 levels signal the need for more
frequent patient follow-up, to either detect early resistance
or to exclude poor adherence to TKI therapy.44 Available
data suggest that a rising level of BCR-ABL1 RNA during
TKI therapy can indeed predict increased risk of subsequent
disease progression, even if MMR has been achieved.39
Although most patients with a TKI-induced CCyR and
a subsequent rise in BCR-ABL1 RNA levels remain in
CCyR, there is a persistent increased risk of both relapse and
a newly developed BCR-ABL1 kinase domain (KD) muta-
tion,39,43,45 which, by itself, is a proven risk factor for
disease progression.4 ELN guidelines consider a rise in
BCR-ABL1 levels at any time during treatment to constitute
a warning of a possible suboptimal response (Table 2).27,33
At the very least, rising BCR-ABL1 levels should warrant
a repeat RT-qPCR within the next 1 to 3 months (NCCN
Guidelines), sooner than the recommended routine testing
interval, the goal being early detection of true disease
progression, and possible intervention before full-ﬂedged
cytogenetic or hematologic relapse.
How high must BCR-ABL1 RNA levels rise to be of
clinical concern? Cutoff values to deﬁne a clinically
signiﬁcant rise in BCR-ABL1 RNA levels vary by laboratory
and therefore have been difﬁcult to standardize. Suggested
transcript rise thresholds that should prompt clinical action
have included a 0.5-log increase,39 a 1-log increase (NCCN
Guidelines), and a twofold (0.3-log) increase.47 A subse-
quent study using a receiver-operating characteristic curve
analysis found that a 2.6-fold (0.41-log) increase in BCR-
ABL1 levels was the optimal cutoff for predicting the
presence of a concomitant KD mutation.43 The negative
predictive value of this 2.6-fold cutoff was 97%, suggesting
that only 3% of patients with transcript rises <2.6-fold will
have a mutation that is missed. This study also showed that
had the NCCN Guidelineerecommended 10-fold (1-log)
transcript rise cutoff been used as a trigger for KD mutation
analysis, the diagnostic sensitivity would have been poor
(26%), with many conﬁrmed mutations missed. Recom-
mendations from the ELN suggest direct mutation testing
when primary treatment with imatinib fails, when the
increase in BCR-ABL1 transcripts leads to loss of MMR, or
whenever there is a suboptimal response (eg, lack of MMR
after 18 months of imatinib).12 Updated NCCN Guidelines
recommend mutation testing when the initial response
is inadequate [no partial cytogenetic response or >10%The Journal of Molecular Diagnostics - jmd.amjpathol.orgBCR-ABL1 (IS) at 3 months, no CCyR at 12 or 18 months],
when there is any sign of loss of response (hematologic or
cytogenetic relapse, or 1-log increase in BCR-ABL1 and loss
of MMR), or when CML progresses to advanced stages of
disease.BCR-ABL1 KD Mutations Directly Inform
Therapeutic Choices
The emergence of BCR-ABL1 KD mutations has been
shown to be associated with an increased likelihood of
subsequent disease progression in patients with TKI-treated
CML.43,46 Although the switch to an alternative TKI, trig-
gered by the ﬁnding of a KD mutation, has never been
shown to directly improve long-term outcomes in
a prospective trial, ELN and NCCN guidelines nevertheless
speciﬁcally recommend a switch to certain TKI agents when
particular mutations are detected.12 Due to the diversity of
mutations, full BCR-ABL1 KD mutation screening is done
in most laboratories by a direct Sanger DNA sequencing
technique that has a detection limit of approximately 20%
mutant allele.11,48 A signiﬁcant majority of BCR-ABL1 KD
mutations cluster to one of four hot spots: the ATP-binding
P-loop (amino acids 248 to 256); the imatinib-binding
region (amino acids 315 to 317); the catalytic domain
(amino acids 350 to 363); and the activation (A)-loop
(amino acids 381 to 402).11 Differential sensitivity to ima-
tinib, dasatinib, nilotinib, bosutinib, and ponatinib has been
demonstrated by these diverse mutant BCR-ABL1 kinases
in in vitro studies.49e52 Because there is often, but not
always, a good correlation between mutation-speciﬁc in vi-
tro resistance and in vivo clinical responses for some, but
not all, KD mutations and TKIs, the identiﬁcation of the
speciﬁc mutation can help to inform the optimal manage-
ment strategy.11,12,49 In particular, the presence of the
common T315I mutation suggests that ponatinib, and no
other TKI, may be effective.19 In addition, NCCN and ELN
guidelines suggest a switch to nilotinib (not dasatinib) for
patients with the V299L, T315A, or F317L/V/I/C mutations;
and a switch to dasatinib (not nilotinib) for patients with the
Y253H, E255K/V, or F359V/C/I mutations.
Aside from point mutations, the BCR-ABL1 KD also
commonly develops insertion/deletion mutations, including
a 35-bp intronic insertion at the exon 8 to 9 junction, an
L248V mutation with deletion of 81 bp of exon 4, an exon 7
deletion, and several others.53e55 Although the clinical and
drug resistance signiﬁcance of most of these insertion-
deletion mutations is still unclear, the very common 35-bp
intronic insertion after exon 8 does not appear to mediate
TKI resistance, in vitro or in vivo.56 The BCR-ABL1 KD also
carries some common single nucleotide polymorphisms that
appear to be wholly benign, including three nonsynonymous
(K247R, F311V, Y320C), and three synonymous (T240T,
T315T, E499E) variants, each of which has no known effect
on TKI binding or drug resistance.57569
Table 3 Sources of Heterogeneity among US Laboratories in
BCR-ABL1 RT-qPCR Assessment
Source of heterogeneity in BCR-ABL1 RT-qPCR measurement
Equipment and reagents
No predominant real-time PCR instrument (brand and model)
used in most laboratories
Multiple sources of PCR primers and probes: commercially
designed versus laboratory designed
Different primers for reverse transcription: random hexamers
versus gene-speciﬁc primers
Multiple manufacturers/distributors of reverse transcriptase and
Taq polymerases
Methodology
No predominant RNA extraction method used across all
laboratories
Variability in RT-qPCR protocols: commercially available kit
versus laboratory-developed assay
No predominant laboratory-developed assay used across all
laboratories
No predominant reference gene used across all laboratories:
ABL1, ACTB, B2M, BCR, G6PD, GAPDH, GUSB, TBP
Multiple types of material used to generate standard curve (or
no standard curve generated): dilutions derived from plasmid
DNA, RNA, cDNA, cell lines
Multiple sources of patient material used in RT-qPCR replicates:
RNA, cDNA, cells, cell extracts/lysates
Reported results
No predominant method for reporting RT-qPCR results used
across all laboratories; BCR-ABL1 level reported as:
Copies per unit of RNA
Ratio, relative to control gene, laboratory median or mean of
diagnostic samples, patient’s previous result, diagnostic
patient sample, diluted or undiluted K562 cells, or other
Log reduction from pre-treatment baseline
Percentage on the IS
Table is compiled from Zhang et al58 and the CAP MRD Survey.
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Figure 1 Distribution of BCR-ABL1 RT-qPCR log-reduction values in
laboratories participating in the CAP MRD proﬁciency testing survey. Once in
each of the years 2009, 2010, and 2011, approximately 100 laboratories
received two blinded samples for BCR-ABL1 RT-qPCR analysis: a baseline
sample containing undiluted K562 cell-line RNA and a post-treatment
sample containing K562 RNA (dilution 1:10,000 in non-CML cell RNA).
Each laboratory measured the BCR-ABL1 RNA ratio by its own validated
method, and reported back to CAP the relative log reduction of the post-
treatment sample compared with the baseline sample. A: Histogram of the
combined log-reduction data from the cumulative 3-year testing period (nZ
300). B: Box-whisker plot of the log-reduction values split by the reference
genes used, either ABL1 (nZ 187) or any other non-ABL1 reference gene (n
Z 111). Information regarding reference gene use was not available for two
laboratories. The arrow on the x axis indicates the expected target log-
reduction value (4.0). The vertical line in the middle of each box is the
median value of the distribution. The notch around the median represents
the 95% CI for the median. The vertical lines at the end of each box are the
25% and 75% values of the distribution. The vertical bars outside of each
box are the 10% and 90% values of the distribution.
Press et alWhat Laboratory-Speciﬁc Factors Limit the
Precision, Accuracy, and Sensitivity of the BCR-
ABL1 RT-qPCR Assay?
The dearth of high-quality, affordable, standardized reagents
remains a substantial barrier to wider adoption of IS-
standardized BCR-ABL1 RT-qPCR assays. Assay-related
heterogeneity affects all aspects of the multistep RT-qPCR
procedure (Table 3), which contributes to the considerable
variability in BCR-ABL1 quantitative values reported by US
clinical diagnostic laboratories [College of American
Pathologists (CAP) Surveys 2012 and Anatomic Pathology
Education Programs. MRD participant summary report,
hereinafter referred to as CAP Survey].58 Several studies
have indicated a need for improvement in BCR-ABL1 RT-
qPCR assay reproducibility (precision) between laborato-
ries and even within laboratories.58e62 For example, in
a study of 38 laboratories that used blinded shared samples,
BCR-ABL1 RT-qPCR results varied by 1.6 to 3 log for the570same sample.58 A more comprehensive and less biased
source of real-world data on BCR-ABL1 RT-qPCR analyt-
ical assay performance is the CAP MRD proﬁciency survey
whereby blinded CML RNA samples are sent biannually to
participating clinical molecular diagnostic laboratories as
part of a proﬁciency testing program required to maintain
laboratory accreditation (CAP Survey). Over each of the
past 3 years (2009, 2010, 2011), one CAP MRD survey per
year has included the same 1 in 10,000 (4-log) dilution of
CML cell-line K562 RNA, along with a comparative sample
containing undiluted K562 RNA. In these surveys, CAP has
required that laboratories report a relative log reduction of
the BCR-ABL1 RNA ratio in the diluted (post-treatment)
sample divided by the undiluted (baseline) sample. Instead
of the expected 4-log difference between samples, andjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Monitoring Molecular Response in CMLdespite efforts to improve assay standardization and preci-
sion by eliminating method-dependent variability from the
log-reduction result calculation, the distribution of reported
log-reduction values (n Z 300) showed considerable assay
imprecision and inaccuracy (Figure 1A). The overall mean
log reduction of 300 reported results from three combined
CAP surveys (2009, 2010, 2011) was 3.3 log (median, 3.4
log), 0.7 log removed from the expected 4-log value. There
was substantial interlaboratory variability (0.99 log SD) in
this cumulative 3-year distribution that was not considerably
different from that observed in the individual surveys [0.8
log SD in 2009 (nZ 87), 1.0 log in 2010 (nZ 108), and
0.9 log in 2011 (n Z 105)]. This high degree of inter-
laboratory imprecisiondeven without accounting for vari-
ability stemming from RNA extraction and other method
biasesdclearly precludes the practical ability to meaning-
fully interpret serial BCR-ABL1 RNA levels when those
measurements are not all performed in the same laboratory,
and reafﬁrms the critical need for improved assay stan-
dardization. Furthermore, these data suggest that many
clinical laboratories are inaccurate in their quantiﬁcation of
BCR-ABL1 RNA, with 32% of laboratories reporting log-
reduction values >1 log (10-fold) removed from the ex-
pected 4-log value.
A signiﬁcant and much-debated source of variability in
the BCR-ABL1 RT-qPCR assay is the choice of reference
gene used to calculate the relative transcript ratio.58,63 In
a direct exploration of this issue, Wang et al63 examined
nine reference genes and deemed GUSB as the most suitable
for BCR-ABL1 RT-qPCR. In another study, Zhang et al58
found BCR to be a more suitable reference gene than
GUSB. Nonetheless, of the seven reference genes used by
approximately 100 CAP-surveyed laboratories, the two
most commonly used are ABL1 and G6PD, together
accounting for over 80% of laboratories (CAP Survey).The Journal of Molecular Diagnostics - jmd.amjpathol.orgAlthough ABL1 is by far the most popular reference gene, it
is actually a rather poor choice given that the PCR primers
typically used for quantitating ABL1 also cross-react and
amplify BCR-ABL1.58,63,64 Thus, the measured level of
ABL1 actually reﬂects levels of BCR-ABL1 plus ABL1, and
ﬂuctuates in samples with varying leukemia burdens. These
sample-speciﬁc ﬂuctuations in reference gene RNA levels
are completely contradictory to the primary deﬁning char-
acteristic of an ideal RT-qPCR reference gene. Thus, the
resulting BCR-ABL1/ABL1 RNA ratio is nonlinear and
falsely low, particularly when the leukemia burden is high.63
When the ABL1 reference gene is used for monitoring
during TKI treatment, the log-reduction from baseline
calculation will be skewed artiﬁcially low, and the resulting
IS value therefore will be falsely high. Consistent with this
prediction, the blinded CAP survey data showed that for the
187 laboratories using ABL1 as the reference gene, the log-
reduction values (mean, 2.9 log  0.07 SE) were signiﬁ-
cantly lower (by 0.9 log; P < 0.0001) than for the 111571
Press et allaboratories using any other non-ABL1 reference gene
(mean, 3.8 log  0.08 SE) (Figure 1B). In other words, the
average laboratory using the ABL1 reference gene falsely
overquantitated BCR-ABL1 RNA by >1 log (>10-fold)
relative to the expected 4-log result. Although this ABL1
reference geneedependent assay bias is perhaps exacer-
bated in this CAP survey that utilizes a cell line (K562) with
a known BCR-ABL1 gene ampliﬁcation, an analogous (but
perhaps lower magnitude) overquantitation phenomenon
would also be expected to occur with any other sample
source.
How Can the BCR-ABL1 RT-qPCR Assay Be
Standardized to the IS of Measurement, by
Which Clinically Relevant Threshold Levels
Have Already Been Deﬁned?
Inadequate clinical laboratory adoption of a standardized
reporting scale for BCR-ABL1 RT-qPCR remains a signiﬁ-
cant barrier to the real-world implementation of the
consensus molecular monitoring clinical practice guidelines
recently put forth in both the US and Europe (NCCN
Guidelines).27 International efforts to better standardize
BCR-ABL1 RT-qPCR reporting have been ongoing for many
years, and have recently resulted in at least two notable
achievements: the creation of an IS of quantitative
measurement for BCR-ABL1 RT-qPCR21 and the availability
of standardized reference material calibrated to the IS and
validated by the World Health Organization (WHO).65
The original samples used in the IRIS study to establish the
anchor values (ie, the pretreatment median standardized
baseline and MMR) for the IS are no longer available, but
quantitative traceability to those original values has been
provided by the Hughes & Branford laboratory in Adelaide,
Australia, which participated in the IRIS study and has
maintained strict assay quality control standards for the past
decade.26,31 Because the BCR-ABL1 IS anchor values
represent absolute, not relative, values and are not dependent
on the pretreatment baseline value of any particular patient,Figure 4 The pathway for use of certiﬁed reference standards for BCR-ABL1
certiﬁed by the WHO. Based on White et al64. The actual assigned IS values for the
0.1%, and 0.01% target values, and depend on the reference gene that was used
572laboratories around the world, using heterogeneous methods
for RT-qPCR (including different reference genes), can adopt
the IS without fundamental technical changes to local stan-
dard operating procedures.31 Two speciﬁc methods are
available for harmonizing a laboratory’s local BCR-ABL1
RT-qPCR assay to the IS: sample sharing with a laboratory
already harmonized to the IS to establish a mathematical
conversion factor (CF),31 and local assay calibration with
reference material that is calibrated to the IS.65
The sample-exchange process for conversion to the IS
involves an exchange of samples with a validated reference
laboratory whose BCR-ABL1 RT-qPCR assay is already
aligned to the IS. The reference BCR-ABL1 RT-qPCR data
from this reference laboratory are compared with those
generated in a ﬁeld laboratory, and a CF is mathematically
derived from simple linear regression and bias analyses.31
This CF is a constant ﬁxed number by which the RT-
qPCR ratio generated in the ﬁeld laboratory is multiplied
to convert to the IS. In a study seeking to align the BCR-
ABL1 RT-qPCR values of 38 ﬁeld laboratories from around
the world to that of the IS-calibrated Adelaide laboratory,
calculated CFs ranged from 0.18 to 13.5 in an initial round
of sample exchanges. In our laboratory, the CF to the IS was
2.22 (Figure 2). With a second round of sample exchanges,
the majority of ﬁeld laboratories were able to validate their
CFs, with performance characteristics such that <10% of
patients who achieved MMR would be misclassiﬁed.31
Although this sample exchange approach successfully
attained its goal of minimizing interlaboratory BCR-ABL1
reporting heterogeneity, several issues remain to be
addressed: i) For laboratories that exchange RNA (and not
raw cell lysates), how should different RNA preparation
methods be controlled for? ii) How stable are the CFs? iii)
How often should the sample exchange procedure be
repeated? and iv) What degree of change to the technical
protocol (eg, different PCR reagent manufacturing lots)
should trigger a recalculation of the CF? Furthermore, the
sample exchange process is challenging, time consuming,
and expensive. The practical difﬁculty of this process is
reﬂected in serial data from the CAP MRD BCR-ABL1molecular monitoring, illustrating traceability back to primary standards
WHO BCR-ABL1 reference material are slightly different from the 10%, 1%,
.
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Monitoring Molecular Response in CMLproﬁciency testing survey (CAP Survey), which shows that,
despite the proven analytical and clinical advantages of the
IS, only a minority of clinical laboratories have successfully
switched to this reporting method (Figure 3). Although
adoption of the IS among clinical laboratories has increased
over the past 3 years, only 45 of 154 (29%) laboratories
surveyed in late 2012 used IS-based reporting (up from 4%
in 2009). This trend of increased adoption of IS-based
reporting, likely due to the recent commercial availability
of BCR-ABL1 RT-qPCR assay reagents that are directly
calibrated to the IS, will likely continue. In the interim,
however, for CML patients being serially monitored in those
71% of laboratories not using the IS, it is unclear how the
efﬁcacy of TKI therapy is being clinically assessed, given
the consensus IS-deﬁned BCR-ABL1 RNA level thresholds
for early response and MMR.
The availability of internationally validated, traceable,
widely available universal reference materials would greatly
facilitate the conversion of BCR-ABL1 testing laboratories
to the IS. Toward this goal, a WHO International Genetic
Reference Panel was recently established and validated
for quantitation of BCR-ABL1 RNA with any of three
commonly used control genes (ABL1, BCR, and GUSB).65
These extensively tested reference materials consist of
a lyophilized admixture of K562 and HL60 cell lines at four
different dilution levels, with BCR-ABL1 RNA levels that
are close to clinical thresholds (eg, MMR) and directly tied
to the IS.65 Unfortunately, only a limited supply of this
primary reference material was created, and it is envisioned
that reference laboratories, commercial reagent vendors, and
other organizations will use this primary material to create
validated large-scale secondary reference materials to be
used as routine calibrators in individual testing laboratories
(Figure 4).65 Several commercial reagent vendors now
market such IS-standardized reagents or calibrators. In
addition, two of these vendors have each recently begun
clinical trials with the aim of providing Food and Drug
Administrationeapproved assay kits that will automatically
incorporate IS-based reporting units for BCR-ABL1.Conclusions
It is now widely accepted that molecular monitoring by serial
BCR-ABL1 RT-qPCR provides essential information on TKI
treatment response in patients with CML. In particular, the
achievement of MMR at 18 months of TKI therapy is recog-
nized as a consensus indicator of successful treatment response
and subsequent good prognosis. More recently, the NCCN
guidelines have included the achievement of early molecular
response, deﬁned as10% BCR-ABL1 (IS) at 3 months post-
TKI initiation, as an important responsemilestone that directly
informs diseasemanagement decisions at this early time point.
Additional data suggest that even lower levels of MRD,
namely CMR (undetectable BCR-ABL1 using an RT-qPCR
assay with sensitivity of 4, 4.5, or 5 log), may affordThe Journal of Molecular Diagnostics - jmd.amjpathol.orgeven better prognosis. The failure to achieve optimal thera-
peutic landmarks, as deﬁned by BCR-ABL1 (IS) values,
conveys an increased risk of poor outcome, and may indicate
the need to switch the TKI agent. Furthermore, increasing
levels of BCR-ABL1 RNA indicate a rising leukemia burden
and confer an increased risk of disease progression and the
appearance of drug-resistantmutations inBCR-ABL1. Regular
monitoring (every 3 to 6 months) with accurate, reproducible,
and standardizedBCR-ABL1RT-qPCR assays is thus required
throughout the course of TKI therapy. Imprecision and inac-
curacy in measuring BCR-ABL1 transcripts can have serious
adverse clinical consequences, and treatable problems of early
relapse or resistance may go unnoticed.
Efforts to facilitate accurate and precise measurements of
BCR-ABL1 RNA were enhanced recently by the validation
of WHO reference standards. It is hoped that the recent
availability of validated secondary reference materials based
on the primary WHO reference standards will encourage
more laboratories to adopt the standardized IS for reporting
of BCR-ABL1 assay results. This should facilitate the
accurate interlaboratory comparison of data, and the
consistent identiﬁcation of patients who have achieved
clinically relevant therapeutic milestones such as early
molecular response or MMR (or even CMR). Improved
reliability of molecular monitoring will enhance the conﬁ-
dence in these measurements to the beneﬁt of clinicians,
laboratories, pathologists, patients, regulators, and payers.
Note Added in Proof
While this manuscript was in preparation for print, the
European LeukemiaNet (ELN) published updated recom-
mendations for management of chronic myeloid leukemia.33
These new ELN recommendations vary from the 2009 ELN
recommendations primarily by the addition of speciﬁc time-
dependent molecular monitoring thresholds for deﬁning
“Optimal,” “Warning” (previously called “Suboptimal”),
and “Failure” categories of TKI responses. In particular, the
2013 ELN recommendations update the information in
Table 2 of this manuscript to include:
 An “Optimal” response is deﬁned by a 3-month post-TKI
BCR-ABL qPCR value below 10% IS, a 6-month post-
TKI BCR-ABL RT-qPCR value below 1% IS, and a 12-
month post-TKI BCR-ABL RT-qPCR value below 0.1%
IS (ie, MMR).
 A “Failed” response (meaning a change of therapy is
recommended) is deﬁned by a 6-month post-TKI BCR-
ABL qPCR value above 10% IS and a 12 month post-TKI
BCR-ABL qPCR value above 1% IS.Acknowledgments
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